Phosphodiesterase 3B: An important regulator of energy homeostasis

Cyclic Nucleotide Phosphodiesterases in Health and Disease

Volumn , Issue , 2006, Pages 79-97

  Degerman, Eva ^a   Manganiello, Vincent ^b  

^a LUND UNIVERSITY   (Sweden)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85132520113     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (118)

1. Francis, S.H., I.V. Turko, and J.D. Corbin. 2001. Cyclic nucleotide phosphodiesterases: Relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1.
2. Manganiello, V., and E. Degerman. 2004. Cyclic nucleotide phosphodiesterases. In Encylopedia of Biological Chemistry, eds. W. Lennarz, and M.D. Lane. New York: Elsevier Science, pp. 501-505.
3. Conti, M., and S.L. Jin. 1999. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 63:1.
4. Shakur, Y., L. Stenson Holst, T. Rahn Landström, et al. 2001. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol 66:241.
5. Ding, B., J. Abe, H. Wei, et al. 2005. A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci USA 102:14771.
6. Ding, B., J. Abe, H. Wei, et al. 2005. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis. Circulation 111:2469.
7. Zmuda-Trzebiatowska, E., A. Oknianska, V. Manganiello, et al. 2006. Role of PDE3B in insulin-induced glucose uptake, GLUT-4 translocation and lipogenesis in primary rat adipocytes. Cell Signal 3:382.
8. Eriksson, J.W., C. Wesslau, and U. Smith. 1994. The cGMP-inhibitable phosphodiesterase modulates glucose transport activation by insulin. Biochim Biophys Acta 1189:163.
9. Zhao, A.Z., M.M. Shinohara, D. Huang, et al. 2000. Leptin induces insulin-like signaling that antagonizes cAMP elevation by glucagon in hepatocytes. J Biol Chem 275:11348.
10. Zhao, A.Z., H. Zhao, J. Teague, et al. 1997. Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B. Proc Natl Acad Sci USA 94:3223.
11. Zhao, A.Z., K.E. Bornfeldt, and J.A. Beavo. 1998. Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. J Clin Invest 102:869.
12. Furman, B., N. Pyne, P. Flatt, et al. 2004. Targeting beta-cell cyclic 3',5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review. J Pharm Pharmacol 56 (12):1477.
13. Springett, G.M., H. Kawasaki, and D.R. Spriggs. 2004. Non-kinase second-messenger signaling: New pathways with new promise. Bioessays 26 (7):730.
14. Maurice, D.H., and R.J. Haslam. 1990. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: Inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 37:671.
15. Fisch, A., J. Michael-Hepp, J. Meyer, et al. 1995. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP. Eur J Pharmacol 289:455.
16. Marcoz, P., A.F. Prigent, M. Lagarde, et al. 1993. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents. Mol Pharmacol 44:1027.
17. Kirstein, M., M. Rivet-Bastide, S. Hatem, et al. 1995. Nitric oxide regulates the calcium current in isolated human atrial myocytes. J Clin Invest 95:794.
18. Maurice, D.H., and R.J. Haslam. 1990. Nitroprusside enhances isoprenaline-induced increases in cAMP in rat aortic smooth muscle. Eur J Pharmacol 191:471.
19. Komas, N., C. Lugnier, and J.C. Stoclet. 1991. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br J Pharmacol 104:495.
20. Weishaar, R.E., M.H. Cain, and J.A. Bristol. 1985. A new generation of phosphodiesterase inhibitors: Multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem 28:537.
21. Alvarez, R., G.L. Banerjee, J.J. Bruno, et al. 1986. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties. Mol Pharmacol 29:554.
22. Manganiello, V., E. Degerman, and M. Elks. 1988. Selective inhibitors of specific phosphodiesterases in intact adipocytes. Methods Enzymol 159:504.
23. Beavo, J.A., and D.H. Reifsnyder. 1990. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 11:150.
24. Komas, N., S. Movsesian, E. Kedev, et al. 1996. cGMP-inhibited phosphodiesterase (PDE3). In Phosphodiesterase inhibitors, eds. C. Schudt, G. Dent, and K.F. Rabe, 89. London: Academic Press.
25. Conti, M., C.B. Andersen, F.J. Richard, et al. 1998. Role of cyclic nucleotide phosphodiesterases in resumption of meiosis. Mol Cell Endocrinol 145:9.
26. Elks, M.L., V.C. Manganiello, and M. Vaughan. 1983. Hormone-sensitive particulate cAMP phosphodiesterase activity in 3T3-L1 adipocytes. Regulation of responsiveness by dexamethasone. J Biol Chem 258:8582.
27. Eriksson, H., M. Ridderstrale, E. Degerman, et al. 1995. Evidence for the key role of the adipocyte cGMP-inhibited cAMP phosphodiesterase in the antilipolytic action of insulin. Biochim Biophys Acta 1266:101.
28. Movsesian, M.A. 2000. Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure. Expert Opin Investig Drug 9:963.
29. Wang, S., J. Cone, M. Fong, et al. 2001. Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol 38 (5):775.
30. Degerman, E., P. Belfrage, A.H. Newman, et al. 1987. Purification of the putative hormone sensitive cyclic AMP phosphodiesterase from rat adipose tissue using a derivative of cilostamide as a novel affinity ligand. J Biol Chem 262:5797.
31. Degerman, E., V.C. Manganiello, A.H. Newman, et al. 1988. Purification, properties and polyclonal antibodies for the particulate, low Km cAMP phosphodiesterase from bovine adipose tissue. Second Messengers Phosphoproteins 12:171.
32. Rascón, A., S. Lindgren, L. Stavenow, et al. 1992. Purification and properties of the cGMP inhibited cAMP phosphodiesterase from bovine aortic smooth muscle. Biochim Biophys Acta 1134:149.
33. Degerman, E., M. Moos Jr., A. Rascón, et al. 1994. Single-step affinity purification, partial structure and properties of human platelet cGMP inhibited cAMP phosphodiesterase. Biochim Biophys Acta 1205:189.
34. LeBon, T.R., J. Kasuya, R.J. Paxton, et al. 1992. Purification and characterization of guanosine 3',5'-monophosphate-inhibited low Km adenosine 3',5'-monophosphate phosphodiesterase from human placental cytosolic fractions. Endocrinology 130:3265.
35. Pyne, N.J., M.E. Cooper, and M.D. Houslay. 1987. The insulin- and glucagon-stimulated 'densevesicle' high-affinity cyclic AMP phosphodiesterase from rat liver. Purification, characterization and inhibitor sensitivity. Biochem J 242:33.
36. Boyes, S., and E.G. Loten. 1988. Purification of an insulin-sensitive cyclic AMP phosphodiesterase from rat liver. Eur J Biochem 174:303.
37. Harrison, S.A., D.H. Reifsnyder, B. Gallis, et al. 1986. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: A receptor for new cardiotonic drugs. Mol Pharmacol 29:506.
38. Grant, P.G., and R.W. Colman. 1984. Purification and characterization of a human platelet cyclic nucleotide phosphodiesterase. Biochemistry 23:1801.
39. Meacci, E., M. Taira, M. Moos Jr., et al. 1992. Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase. Proc Natl Acad Sci USA 89:3721.
40. Taira, M., S.C. Hockman, J.C. Calvo, et al. 1993. Molecular cloning of the rat adipocyte hormone sensitive cyclic GMP-inhibited cyclic nucleotide phosphodiesterase. J Biol Chem 268:18573.
41. Miki, T., M. Taira, S. Hockman, et al. 1996. Characterization of the cDNA and gene encoding human PDE3B, the cGIP1 isoform of the human cyclic GMP-inhibited cyclic nucleotide phosphodiesterase family. Genomics 36:476.
42. Lobbert, R.W., A. Winterpacht, B. Seipel, et al. 1996. Molecular cloning and chromosomal assignment of the human homologue of the rat cGMP-inhibited phosphodiesterase 1 (PDE3A)-a gene involved in fat metabolism located at 11p 15.1. Genomics 37:211.
43. Kasuya, J., H. Goko, and Y. Fujita-Yamaguchi. 1995. Multiple transcripts for the human cardiac form of the cGMP-inhibited cAMP phosphodiesterase. J Biol Chem 270:14305.
44. Hambleton, R., J. Krall, E. Tikishvili, et al. 2005. Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. J Biol Chem 280:39168.
45. Choi, Y.H., D. Ekholm, J. Krall, et al. 2001. Identification of a novel isoform of the cyclic nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes. Biochem J 353:41.
46. Leroy, M.-J., E. Degerman, M. Taira, et al. 1996. Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells. Biochemistry 35:10194.
47. He, R., N. Komas, D. Ekholm, et al. 1998. Expression and characterization of deletion recombinants of two cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE-3). Cell Biochem Biophys 29:89.
48. Kenan, Y., T. Murata, Y. Shakur, et al. 2000. Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE3) isoforms. J Biol Chem 275:12331.
49. Shakur, Y., K. Takeda, Y. Kenan, et al. 2000. Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum. J Biol Chem 275:38749.
50. Smith, C.J., J. Krall, V.C. Manganiello, et al. 1993. Cytosolic and sarcoplasmic reticulum-associated low Km, cGMP-inhibited cAMP phosphodiesterase in mammalian myocardium. Biochem Biophys Res Commun 190:516.
51. Liu, H., and D.H. Maurice. 1998. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: Differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol 125:1501.
52. Varnerin, J.P., C.C. Chung, S.B. Patel, et al. 2004. Expression, refolding, and purification of recombinant human phosphodiesterase 3B: Definition of the N-terminus of the catalytic core. Protein Expr Purif35 (2):225.
53. Scapin, G., S.B. Patel, C. Chung, et al. 2004. Crystal structure of human phosphodiesterase 3B: Atomic basis for substrate and inhibitor specificity. Biochemistry 43 (20):6091.
54. Cheung, P.P., H. Xu, M.M. McLaughlin, et al. 1996. Human platelet cGI-PDE: Expression in yeast and localization of the catalytic domain by deletion mutagenesis. Blood 88 (4):1321.
55. Colman, R.W. 2004. Platelet cyclic adenosine monophosphate phosphodiesterases: Targets for regulating platelet-related thrombosis. Semin Thromb Hemost 30 (4):451.
56. Zhang, W., H. Ke, and R.W. Colman. 2002. Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis. Mol Pharmacol 62 (3):514.
57. Zhang, W., H. Ke, A.P. Tretiakova, et al. 2001. Identification of overlapping but distinct cAMP and cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagenesis and molecular modeling based on crystalline PDE4B. Protein Sci 10 (8):1481.
58. Ke, H. 2004. Implications of PDE4 structure on inhibitor selectivity across PDE families. Int J Impot Res 16 (Suppl. 1):24.
59. Reinhardt, R.R., E. Chin, J. Zhou, et al. 1995. Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J Clin Invest 95:1528.
60. Reinhardt, R.R., and C.A. Bondy. 1996. Differential cellular pattern of gene expression for two distinct cGMP-inhibited cyclic nucleotide phosphodiesterases in developing and mature rat brain. Neuroscience 72:567.
61. Han, S.J., and M. Conti. 2006. New pathways from PKA to the Cdc2/cyclin B complex in oocytes: Wee1B as a potential PKA substrate. Cell Cycle 5 (3):227.
62. Masciarelli, S., K. Horner, C. Liu, et al. 2004. Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility. J Clin Invest 114 (2):196.
63. Hun Choi, Y., S. Park, S. Hockman, et al. Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B (mPDE3B)-null mice. J. Clin Invest (in press).
64. Grant, P.G., A.F. Mannarino, and R.W. Colman. 1988. cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci USA 85:9071.
65. Macphee, C.H., D.H. Reifsnyder, T.A. Moore, et al. 1988. Phosphorylation results in activation of a cAMP phosphodiesterase in human platelets. J Biol Chem 263:10353.
66. Maurice, D.H., D. Palmer, D.G. Tilley, et al. 2003. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 64:533.
67. Kono, T., F.W. Robinson, and J.A. Sarver. 1975. Insulin-sensitive phosphodiesterase. Its localization, hormonal stimulation, and oxidative stabilization. J Biol Chem 250 (19):7826.
68. Nilsson, R., F. Ahmad, K. Sward, et al. 2006 Plasma membrane cyclic nucleotide phosphodiesterase 3B (PDE3B) is associated with caveolae in primary rat adipocytes. Cell Signal 18 (10):1713.
69. Cohen, A.W., T.P. Combs, P.E. Scherer, et al. 2003. Role of caveolin and caveolae in insulin signaling and diabetes. Am J Physiol Endocrinol Metab 285 (6):E1151.
70. Razani, B., T.P. Combs, X.B. Wang, et al. 2002. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem 277:8635.
71. Liu, P., M. Rudick, and R.G. Anderson. 2002. Multiple functions of caveolin-1. J Biol Chem 277:41295.
72. Botham, K.M. 1992. Cyclic AMP and the regulation of cholesterol metabolism. Biochem Soc Trans 2:454.
73. Rondinone, C.M., E. Carvalho, T. Rahn, et al. 2000. Phosphorylation of PDE3B by phosphatidylinositol 3-kinase associated with the insulin receptor. J Biol Chem 275:10093.
74. Kitamura, T., Y. Kitamura, S. Kuroda, et al. 1999. Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase. Akt Mol Cell Biol 9:6286.
75. Onuma, H., H. Osawa, K. Yamada, et al. 2002. Identification of the insulin-regulated interaction of phosphodiesterase 3B with 14-3-3 beta protein. Diabetes 51:3362.
76. Pozuelo Rubio, M., D.G. Campbell, N.A. Morrice, et al. 2005. Phosphodiesterase 3A binds to 14-3-3 proteins in response to PMA-induced phosphorylation of Ser428. Biochem J 392 (Pt 1):163.
77. Onuma, H., H. Osawa, T. Ogura, et al. 2005. A newly identified 50 kDa protein, which is associated with phosphodiesterase 3B, is phosphorylated by insulin in rat adipocytes. Biochem Biophys Res Commun 337:976.
78. Elbatarny, H.S., and D.H. Maurice. 2005. Leptin-mediated activation of human platelets: Involvement of a leptin receptor and phosphodiesterase 3A-containing cellular signaling complex. Am J Physiol Endocrinol Metab 289 (4):695.
79. Patrucco, E., A. Notte, L. Barberis, et al. 2004. PI3K-gamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118 (3):375.
80. Ahmad, F., G. Gao, L.M. Wang, et al. 1999. IL3 and IL4 activate cyclic nucleotide phosphodiesterases 3 (PDE3) and 4 (PDE4) by different mechanisms in FDCP2 myeloid cells. J Immunol 162:4864.
81. Zhao, A.Z., J.N. Huan, S. Gupta, et al. 2002. A phosphatidylinositol 3-kinase phosphodiesterase 3B-cyclic AMP pathway in hypothalamic action of leptin on feeding. Nat Neurosci 8:727.
82. Degerman, E., C.J. Smith, H. Tornqvist, et al. 1990. Evidence that insulin and isoprenaline activate the cGMP-inhibited low-Km cAMP phosphodiesterase in rat fat cells by phosphorylation. Proc Natl Acad Sci USA 87:533.
83. Smith, C.J., V. Vasta, E. Degerman, et al. 1991. Hormone-sensitive cyclic GMP-inhibited cyclic AMP phosphodiesterase in rat adipocytes. Regulation ofinsulin- and cAMP-dependent activation by phosphorylation. J Biol Chem 266:13385.
84. Smith, C.J., and V.C. Manganiello. 1989. Role of hormone-sensitive low Km cAMP phosphodiesterase in regulation of cAMP-dependent protein kinase and lipolysis in rat adipocytes. Mol Pharmacol 35:381.
85. Holm, C., D. Langin, V. Manganiello, et al. 1997. Regulation of hormone-sensitive lipase activity in adipose tissue. Methods Enzymol 286:45.
86. Londos, C., R.C. Honnor, and G.S. Dhillon. 1985. cAMP-dependent protein kinase and lipolysis in rat adipocytes. III. Multiple modes of insulin regulation of lipolysis and regulation of insulin responses by adenylate cyclase regulators. J Biol Chem 260:15139.
87. Rahn, T., M. Ridderstråle, H. Tornqvist, et al. 1994. Essential role of phosphatidylinositol 3-kinase in insulin-induced activation and phosphorylation of the cGMP-inhibited cAMP phosphodiesterase in rat adipocytes. Studies using the selective inhibitor wortmannin. FEBS Lett 350:314.
88. Wijkander, J., T. Rahn Landstrom, V. Manganiello, et al. 1998. Insulin-induced phosphorylation and activation of phosphodiesterase 3B in rat adipocytes: Possible role for protein kinase B but not mitogen-activated protein kinase or p70 S6 kinase. Endocrinology 139:219.
89. Ahmad, F., L.N. Cong, L. Stenson Holst, et al. 2000. Cyclic nucleotide phosphodiesterase 3B is a downstream target of protein kinase B and may be involved in regulation of effects of protein kinase B on thymidine incorporation in FDCP2 cells. J Immunol 164 (9):4678.
90. Gettys, T.W., A.J. Vine, M.F. Simonds, et al. 1988. Activation of the particulate low Km phosphodiesterase of adipocytes by addition of cAMP-dependent protein kinase. J Biol Chem 263:10359.
91. Rascón, A., E. Degerman, M. Taira, et al. 1994. Identification of the phosphorylation site in vitro for cAMP-dependent protein kinase on the rat adipocyte cGMP-inhibited cAMP phosphodiesterase. J Biol Chem 269:11962.
92. Rahn, T., L. Rönnstrand, M.-J. Leroy, et al. 1996. Identification of the site in the cGMP-inhibited phosphodiesterase phosphorylated in adipocytes in response to insulin and isoproterenol. J Biol Chem 271:11575.
93. Resjö, S., A. Oknianska, S. Zolnierowicz, et al. 1999. Phosphorylation and activation of phosphodiesterase type 3B (PDE3B) in adipocytes in response to serine/threonine phosphatase inhibitors: Deactivation of PDE3B in vitro by protein phosphatase type 2A. Biochem J 341:839.
94. Boden, G. 1997. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3.
95. McGarry, J.D., and R.L. Dobbins. 1999. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 42:128.
96. Reaven, G.M. 1995. The fourth musketeer-from Alexandre Dumas to Claude Bernard. Diabetologia 38:3.
97. Frayn, K.N. 1993. Insulin resistance and lipid metabolism. Curr Opin Lipidol 4:197.
98. Frayn, K.N., C.M. Williams, and P. Arner. 1996. Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases? Clin Sci (Lond) 90:243.
99. Engfeldt, P., P. Arner, J. Bolinder, et al. 1982. Phosphodiesterase activity in human subcutaneous adipose tissue in insulin- and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 55:983.
100. Nagaoka, T., T. Shirakawa, T.W. Balon, et al. 1998. Cyclic nucleotide phosphodiesterase 3 expression in vivo: Evidence for tissue-specific expression of phosphodiesterase 3A or 3B mRNA and activity in the aorta and adipose tissue of atherosclerosis-prone insulin-resistant rats. Diabetes 47:1135.
101. Tang, Y., H. Osawa, H. Onuma, et al. 1999. Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice. Diabetes 48:1830.
102. Tang, Y., H. Osawa, H. Onuma, et al. 2001. Adipocyte-specific reduction of phosphodiesterase 3B gene expression and its restoration by JTT-501 in the obese, diabetic KKAy mouse. Eur J Endocrinol 145:93.
103. Tang, Y., H. Osawa, H. Onuma, et al. 2001. Phosphodiesterase 3B gene expression is enhanced in the liver but reduced in the adipose tissue of obese insulin resistant db/db mouse. Diabetes Res Clin Pract 54:145.
104. Rahn Landstrom, T., J. Mei, M. Karlsson, et al. 2000. Down-regulation of cyclic-nucleotide phosphodiesterase 3B in 3T3-L1 adipocytes induced by tumour necrosis factor alpha and cAMP. Biochem J 346 (Pt 2):337.
105. Mei, J., L. Stenson Holst, T. Rahn Landstrom, et al. 2002. C(2)-ceramide influences the expression and insulin-mediated regulation of cyclic nucleotide phosphodiesterase 3B and lipolysis in 3T3-L1 adipocytes. Diabetes 51:631.
106. Zhang, H.H., M. Halbleib, F. Ahmad, et al. 2002. Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 51:2929.
107. Ryden, M., A. Dicker, V. van Harmelen, et al. 2002. Mapping of early signaling events in tumor necrosis factor-alpha-mediated lipolysis in human fat cells. J Biol Chem 277:1085.
108. Degerman, E., V. Manganiello, J.J. Holst, et al. 2004. Milrinone efficiently potentiates insulin secretion induced by orally but not intravenously administered glucose in C57BL6J mice. Eur J Pharmacol 498:319.
109. Cheung, P., G. Yang, and G. Boden. 2003. Milrinone, a selective phosphodiesterase 3 inhibitor, stimulates lipolysis, endogenous glucose production, and insulin secretion. Metabolism 52:1496.
110. Cases, J.A., I. Gabriely, X.H. Ma, et al. 2001. Physiological increase in plasma leptin markedly inhibits insulin secretion in vivo. Diabetes 50:348.
111. Cheung, P., G. Yang, and G. Boden. 2001. Milrinone, a selective phosphodiesterase 3 inhibitor, stimulates lipolysis, endogenous glucose production, and insulin secretion. Metabolism 52:1496.
112. El-Metwally, M., R. Shafiee-Nick, N.J. Pyne, et al. 1997. The effect of selective phosphodiesterase inhibitors on plasma insulin concentrations and insulin secretion in vitro in the rat. Eur J Pharmacol 324:227.
113. Nakaya, Y., A. Minami, S. Sakamoto, et al. 1999. Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM. Diabetes Obes Metab 1:37.
114. Parker, J.C., M.A. VanVolkenburg, N.A. Nardone, et al. 1997. Modulation of insulin secretion and glycemia by selective inhibition of cyclic AMP phosphodiesterase III. Biochem Biophys Res Commun 236:665.
115. Shafiee-Nick, R., N.J. Pyne, and B.L. Furman. 1995. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity. Br J Pharmacol 115:1486.
116. Yang, G., and L. Li. 2003. In vivo effects of phosphodiesterase III inhibitors on glucose metabolism and insulin sensitivity. J Chin Med Assoc 66:210.
117. Osawa, H., T. Niiya, H. Onuma, et al. 2003. Systematic search for single nucleotide polymorphisms in the 5' flanking region of the human phosphodiesterase 3B gene: Absence of evidence for major effects of identified polymorphisms on susceptibility to Japanese type 2 diabetes. Mol Genet Metab 79:43.
118. Yechoor, V.K., M.-E. Patti, K. Ueki, et al. 2004. Distinct pathways of insulin-regulated versus diabetes-regulated gene expression: An in vivo analysis in MIRKO mice. Proc Natl Acad Sci USA 101:16525.